RXRX Recursion Pharmaceuticals Inc

$RXRX Someone is scared… 🚀 Short interest plunged 20.8M shares (−11.63%), from 178.7M to 157.9M as of Sept. 30! Days to cover dropped from 12.56 to 6.13. Bulls gaining momentum ahead of November’s REC-4881 catalyst! 🔥

$RXRX that dip this morning was fo flush out retail positions so market makers, tutes, and hedges can get more shares for cheap. Welcome to wallstreet. Hold those shares

$RXRX another partner and support would fuel this. Likely to happen with ai and health care being integrated. Being short here is dangerous!!!!!

$RXRX Perfect timing for market rotation into AI Biotech from semis and data centres.Ever been more bullish in this...

$RXRX | Q4 2026 CATALYST TIMELINE 🚀 📅 Oct 28 — FDA rare-disease framework meeting. Potential tailwind for REC-4881's regulatory pathway. 📅 Nov 2 — REC-4881 Phase 1b/2 clinical presentation, including real-world registry comparisons. 📅 November (TBD) — Q3 earnings and pipeline updates. 📅 Q4 (TBD) — FDA regulatory feedback on REC-4881. Could define the path toward a registrational trial in 2027. 📅 By year-end — Additional REC-1245 oncology data expected. 📅 2H 2026 target — REC-7735 Phase 1/2 trial initiation. The bigger picture: 47% median polyp reduction, FDA Fast Track + Orphan Drug designations, and a recently strengthened cash runway into 2029. October 28 isn't an RXRX approval event. But the timing of FDA rare-disease reforms, REC-4881 data, and upcoming regulatory feedback is worth watching. Multiple catalysts. Multiple shots on goal. Bullish into year-end. $RXRX

$RXRX Just out from LinkedIn $RXRX Najat: Sanofi’s optioned oral drug candidate targets two inflammatory disease targets, with Phase 1 planned for 2027—$10M triggered, $144M received across the collaboration, and $300M+ in potential additional milestones plus double-digit royalties if approved. Sanofi funds further development. 💊💰

$RXRX Been saying this for a long time. Patience is the key. Not talking about bullshit actions at this stage ups/downs

$RXRX It will be sweet for those of us who have been here more than 2 yrs to see this @ $43 instead of $4.30 in 2027😂🚀

$RXRX Listen : there are no such companies as Recursion nowadays... AI+Biotech+innovation+undervalued stock... mmmmh I like it, baby.

$RXRX Nov 2: exact REC-4881 Presidential Plenary presentation slot confirmed—2:30–2:45 PM MST / 4:30–4:45 PM EST / 22:30–22:45 CET. Mayo Clinic’s Dr. Lisa Boardman presents updated FAP safety/efficacy data contextualized with real-world registry data. Q3 earnings also due after market close. Monday is the day

$RXRX BlackRock: 50.30M shares (9.45%) — Bought 7.11M ARK Invest: 41.34M shares (7.76%) — Bought 1.12M State Street: 34.71M shares (6.52%) — Bought 6.22M Vanguard: 31.13M shares (5.85%) — Bought 8.37M Follow the smart $$$ 💪💪💪

$RXRX Are the remaining short sellers comfortable holding through November 2? Approximately 158 million shares are STILL short. That’s an enormous amount of potential future buying if shorts decide to cover.

$RXRX They just proved that have a drug making pipeline. They proved AI can successfully create new medicine. THIS IS HUGE. I suspect we see a big pump and short covering.

$RXRX Nice day to add some more. One of these days between now until Nov 2 they will drop some news and you will never see these levels again.

$RXRX The FDA wants greater involvement from patients and medical experts. And Recursion is bringing together: Mayo Clinic researchers on November 2. Medical experts on November 3. Patients living with FAP on November 3. That is consistent with the FDA’s broader direction. “FDA is not lowering the bar for rare disease, but it may be making the path to approval less of a guessing game,” Schwartz wrote.

$RXRX Recursion Pharmaceuticals (RXRX) stands at the intersection of artificial intelligence and biotechnology, potentially transforming drug discovery forever. With powerful AI platforms, massive biological datasets, strategic pharmaceutical partnerships, a $10 million Sanofi milestone, and $200 million in fresh financing, Recursion is building momentum. Upcoming clinical catalysts could unlock significant value as computing power accelerates scientific breakthroughs. While risks remain, the long-term opportunity is extraordinary. RXRX isn’t simply developing new medicines; it’s pioneering a future where AI could revolutionize healthcare and reshape the pharmaceutical industry.

$RXRX The new shares represent 11.5% increase in share count. They bought at 3.25/share. We got positive clinical results, and more news pending 3.25 level will likely hold strongly if price gets down there again. If we get good news nov 2, bye bye 3s, and maybe 4s forever

$RXRX it’s crazy how it dipped and ripped this morning. Sorry if your stop loss was triggered. Price is still cheap long term

$RXRX #love the recovery after the offering. $5 is nearing, next up earnings and r&d updates. Proud owner ! .

$RXRX 5$ before Halloween , shorts are gonna have to close their lights on halloween and say sorry to the kids because they couldn’t afford candy anymore